Details of the Drug

General Information of Drug (ID: DMKITQE)

Drug Name
Amoxapine
Synonyms
Amoxan; Amoxapina; Amoxapinum; Amoxepine; Ascendin; Asendin; Asendis; Defanyl; Demolox; Desmethylloxapin; Desmethylloxapine; Moxadil; CL 67772; A-129; Amoxapina [INN-Spanish]; Amoxapinum [INN-Latin]; Asendin (TN); Asendis (TN); CL-67772; Defanyl (TN); Demolox (TN); KS-1197; Moxadil (TN); CL-67,772; Amoxapine (JP15/USP/INN); Amoxapine [USAN:BAN:INN:JAN]; 2-Chlor-11-(1-piperazinyl)dibenz(b,f)(1,4)oxazepin; 2-Chloro-11-(1-piperazinyl)-dibenz[b,f][1,4]oxazepine; 2-Chloro-11-(1-piperazinyl)dibenz(b,f)(1,4)oxazepine; 2-Chloro-11-(1-piperazinyl)dibenz[b,f][1,4]oxazepine; 2-chloro-11-(piperazin-1-yl)dibenzo[b,f][1,4]oxazepine; 2-chloro-11-piperazin-1-yldibenzo[b,f][1,4]oxazepine; 8-chloro-6-piperazin-1-ylbenzo[b][1,4]benzoxazepine
Indication
Disease Entry ICD 11 Status REF
Major depressive disorder 6A70.3 Approved [1], [2], [3]
Therapeutic Class
Antidepressants
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 313.8
Topological Polar Surface Area (xlogp) 2.6
Rotatable Bond Count (rotbonds) 1
Hydrogen Bond Donor Count (hbonddonor) 1
Hydrogen Bond Acceptor Count (hbondacc) 3
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [4]
Half-life
The concentration or amount of drug in body reduced by one-half in 8 hours [5]
Metabolism
The drug is metabolized via the liver [6]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 31.86849 micromolar/kg/day [7]
Chemical Identifiers
Formula
C17H16ClN3O
IUPAC Name
8-chloro-6-piperazin-1-ylbenzo[b][1,4]benzoxazepine
Canonical SMILES
C1CN(CCN1)C2=NC3=CC=CC=C3OC4=C2C=C(C=C4)Cl
InChI
InChI=1S/C17H16ClN3O/c18-12-5-6-15-13(11-12)17(21-9-7-19-8-10-21)20-14-3-1-2-4-16(14)22-15/h1-6,11,19H,7-10H2
InChIKey
QWGDMFLQWFTERH-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
2170
ChEBI ID
CHEBI:2675
CAS Number
14028-44-5
DrugBank ID
DB00543
TTD ID
D09IOI
VARIDT ID
DR01091
INTEDE ID
DR0103
ACDINA ID
D00034

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Norepinephrine transporter (NET) TTAWNKZ SC6A2_HUMAN Inhibitor [8]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 2D6 (CYP2D6)
Main DME 		DECB0K3 CP2D6_HUMAN Substrate [9]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

ICD Disease Classification 06 Mental, behavioural or neurodevelopmental disorder
Disease Class ICD-11: 6A20 Schizophrenia
The Studied Tissue Pre-frontal cortex
The Studied Disease Major depressive disorder [ICD-11:6A20]
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Norepinephrine transporter (NET) DTT SLC6A2 7.05E-01 7.02E-03 0.07
Cytochrome P450 2D6 (CYP2D6) DME CYP2D6 5.64E-01 2.36E-02 1.75E-01
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Amoxapine
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Cyclobenzaprine DM1YBRM Major Additive serotonergic effects by the combination of Amoxapine and Cyclobenzaprine. Depression [6A70-6A7Z] [28]
Vilazodone DM4LECQ Major Additive serotonergic effects by the combination of Amoxapine and Vilazodone. Depression [6A70-6A7Z] [28]
Nefazodone DM4ZS8M Major Additive serotonergic effects by the combination of Amoxapine and Nefazodone. Depression [6A70-6A7Z] [28]
Paroxetine DM5PVQE Major Decreased metabolism of Amoxapine caused by Paroxetine mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [29]
Selegiline DM6034S Major Additive serotonergic effects by the combination of Amoxapine and Selegiline. Depression [6A70-6A7Z] [30]
Vortioxetine DM6F1PU Major Additive serotonergic effects by the combination of Amoxapine and Vortioxetine. Depression [6A70-6A7Z] [28]
Isocarboxazid DMAF1NB Major Additive serotonergic effects by the combination of Amoxapine and Isocarboxazid. Depression [6A70-6A7Z] [30]
Milnacipran DMBFE74 Major Additive serotonergic effects by the combination of Amoxapine and Milnacipran. Depression [6A70-6A7Z] [28]
Escitalopram DMFK9HG Major Increased risk of prolong QT interval by the combination of Amoxapine and Escitalopram. Depression [6A70-6A7Z] [31]
Tranylcypromine DMGB5RE Major Additive serotonergic effects by the combination of Amoxapine and Tranylcypromine. Depression [6A70-6A7Z] [30]
Desvenlafaxine DMHD4PE Major Additive serotonergic effects by the combination of Amoxapine and Desvenlafaxine. Depression [6A70-6A7Z] [28]
OPC-34712 DMHG57U Moderate Additive anticholinergic effects by the combination of Amoxapine and OPC-34712. Depression [6A70-6A7Z] [32]
Phenelzine DMHIDUE Major Additive serotonergic effects by the combination of Amoxapine and Phenelzine. Depression [6A70-6A7Z] [30]
Clomipramine DMINRKW Moderate Additive anticholinergic effects by the combination of Amoxapine and Clomipramine. Depression [6A70-6A7Z] [32]
Trazodone DMK1GBJ Major Additive serotonergic effects by the combination of Amoxapine and Trazodone. Depression [6A70-6A7Z] [28]
Doxepin DMPI98T Moderate Additive anticholinergic effects by the combination of Amoxapine and Doxepin. Depression [6A70-6A7Z] [32]
Maprotiline DMPWB7T Moderate Additive anticholinergic effects by the combination of Amoxapine and Maprotiline. Depression [6A70-6A7Z] [32]
⏷ Show the Full List of 17 DDI Information of This Drug
Coadministration of a Drug Treating the Disease Different from Amoxapine (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Methylene blue DMJAPE7 Major Additive serotonergic effects by the combination of Amoxapine and Methylene blue. Acquired methaemoglobinaemia [3A93] [30]
Ivosidenib DM8S6T7 Major Increased risk of prolong QT interval by the combination of Amoxapine and Ivosidenib. Acute myeloid leukaemia [2A60] [33]
Midostaurin DMI6E0R Moderate Increased risk of prolong QT interval by the combination of Amoxapine and Midostaurin. Acute myeloid leukaemia [2A60] [34]
Idarubicin DMM0XGL Moderate Increased risk of prolong QT interval by the combination of Amoxapine and Idarubicin. Acute myeloid leukaemia [2A60] [34]
Daunorubicin DMQUSBT Moderate Increased risk of prolong QT interval by the combination of Amoxapine and Daunorubicin. Acute myeloid leukaemia [2A60] [34]
Arn-509 DMT81LZ Moderate Increased risk of prolong QT interval by the combination of Amoxapine and Arn-509. Acute myeloid leukaemia [2A60] [35]
Gilteritinib DMWQ4MZ Moderate Increased risk of prolong QT interval by the combination of Amoxapine and Gilteritinib. Acute myeloid leukaemia [2A60] [36]
Oliceridine DM6MDCF Moderate Additive CNS depression effects by the combination of Amoxapine and Oliceridine. Acute pain [MG31] [37]
Scopolamine DMOM8AL Moderate Additive anticholinergic effects by the combination of Amoxapine and Scopolamine. Addictive disorder [6C50-6C5Z] [32]
Phenyltoloxamine DMKAEQW Moderate Additive anticholinergic effects by the combination of Amoxapine and Phenyltoloxamine. Allergic/hypersensitivity disorder [4A80-4A8Z] [38]
Tripelennamine DMZBU15 Moderate Additive anticholinergic effects by the combination of Amoxapine and Tripelennamine. Allergic/hypersensitivity disorder [4A80-4A8Z] [32]
Memantine DMD9WSC Moderate Additive anticholinergic effects by the combination of Amoxapine and Memantine. Alzheimer disease [8A20] [32]
Galantamine DMEO794 Moderate Antagonize the effect of Amoxapine when combined with Galantamine. Alzheimer disease [8A20] [39]
Rivastigmine DMG629M Moderate Antagonize the effect of Amoxapine when combined with Rivastigmine. Alzheimer disease [8A20] [39]
Donepezil DMIYG7Z Moderate Antagonize the effect of Amoxapine when combined with Donepezil. Alzheimer disease [8A20] [39]
Metronidazole DMTIVEN Minor Increased risk of prolong QT interval by the combination of Amoxapine and Metronidazole. Amoebiasis [1A36] [40]
Ivabradine DM0L594 Major Increased risk of ventricular arrhythmias by the combination of Amoxapine and Ivabradine. Angina pectoris [BA40] [35]
Bepridil DM0RKS4 Major Increased risk of prolong QT interval by the combination of Amoxapine and Bepridil. Angina pectoris [BA40] [41]
Dronedarone DMA8FS5 Major Increased risk of prolong QT interval by the combination of Amoxapine and Dronedarone. Angina pectoris [BA40] [34]
Bedaquiline DM3906J Major Increased risk of prolong QT interval by the combination of Amoxapine and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [42]
Hydroxyzine DMF8Y74 Moderate Additive anticholinergic effects by the combination of Amoxapine and Hydroxyzine. Anxiety disorder [6B00-6B0Z] [32]
Cilostazol DMZMSCT Moderate Increased risk of prolong QT interval by the combination of Amoxapine and Cilostazol. Arterial occlusive disease [BD40] [34]
Voriconazole DMAOL2S Moderate Increased risk of prolong QT interval by the combination of Amoxapine and Voriconazole. Aspergillosis [1F20] [34]
Posaconazole DMUL5EW Moderate Increased risk of prolong QT interval by the combination of Amoxapine and Posaconazole. Aspergillosis [1F20] [34]
Desipramine DMT2FDC Moderate Additive anticholinergic effects by the combination of Amoxapine and Desipramine. Attention deficit hyperactivity disorder [6A05] [32]
Ofloxacin DM0VQN3 Moderate Increased risk of prolong QT interval by the combination of Amoxapine and Ofloxacin. Bacterial infection [1A00-1C4Z] [43]
Clarithromycin DM4M1SG Moderate Increased risk of prolong QT interval by the combination of Amoxapine and Clarithromycin. Bacterial infection [1A00-1C4Z] [34]
Sulfamethoxazole DMB08GE Minor Increased risk of prolong QT interval by the combination of Amoxapine and Sulfamethoxazole. Bacterial infection [1A00-1C4Z] [34]
Sparfloxacin DMB4HCT Major Increased risk of prolong QT interval by the combination of Amoxapine and Sparfloxacin. Bacterial infection [1A00-1C4Z] [43]
Linezolid DMGFPU2 Major Additive serotonergic effects by the combination of Amoxapine and Linezolid. Bacterial infection [1A00-1C4Z] [44]
Gemifloxacin DMHT34O Moderate Increased risk of prolong QT interval by the combination of Amoxapine and Gemifloxacin. Bacterial infection [1A00-1C4Z] [43]
Norfloxacin DMIZ6W2 Moderate Increased risk of prolong QT interval by the combination of Amoxapine and Norfloxacin. Bacterial infection [1A00-1C4Z] [43]
Levofloxacin DMS60RB Moderate Increased risk of prolong QT interval by the combination of Amoxapine and Levofloxacin. Bacterial infection [1A00-1C4Z] [43]
Lomefloxacin DMVRH9C Moderate Increased risk of prolong QT interval by the combination of Amoxapine and Lomefloxacin. Bacterial infection [1A00-1C4Z] [34]
Telithromycin DMZ4P3A Moderate Increased risk of prolong QT interval by the combination of Amoxapine and Telithromycin. Bacterial infection [1A00-1C4Z] [34]
Retigabine DMGNYIH Moderate Increased risk of prolong QT interval by the combination of Amoxapine and Retigabine. Behcet disease [4A62] [34]
Cariprazine DMJYDVK Moderate Additive anticholinergic effects by the combination of Amoxapine and Cariprazine. Bipolar disorder [6A60] [32]
Loperamide DMOJZQ9 Moderate Additive antimotility effects by the combination of Amoxapine and Loperamide. Bowel habit change [ME05] [45]
Eribulin DM1DX4Q Moderate Increased risk of prolong QT interval by the combination of Amoxapine and Eribulin. Breast cancer [2C60-2C6Y] [34]
Lapatinib DM3BH1Y Moderate Increased risk of prolong QT interval by the combination of Amoxapine and Lapatinib. Breast cancer [2C60-2C6Y] [34]
Tamoxifen DMLB0EZ Moderate Increased risk of prolong QT interval by the combination of Amoxapine and Tamoxifen. Breast cancer [2C60-2C6Y] [34]
Acetylcholine DMDF79Z Moderate Antagonize the effect of Amoxapine when combined with Acetylcholine. Cataract [9B10] [46]
PF-04449913 DMSB068 Moderate Increased risk of prolong QT interval by the combination of Amoxapine and PF-04449913. Chronic myelomonocytic leukaemia [2A40] [47]
Umeclidinium DM4E8O9 Moderate Additive anticholinergic effects by the combination of Amoxapine and Umeclidinium. Chronic obstructive pulmonary disease [CA22] [48]
Tiotropium DMFDC0Q Moderate Additive anticholinergic effects by the combination of Amoxapine and Tiotropium. Chronic obstructive pulmonary disease [CA22] [48]
Revefenacin DMMP5SI Moderate Additive anticholinergic effects by the combination of Amoxapine and Revefenacin. Chronic obstructive pulmonary disease [CA22] [48]
Dihydrocodeine DMB0FWL Moderate Additive serotonergic effects by the combination of Amoxapine and Dihydrocodeine. Chronic pain [MG30] [37]
Levomilnacipran DMV26S8 Major Additive serotonergic effects by the combination of Amoxapine and Levomilnacipran. Chronic pain [MG30] [28]
Olopatadine DMKMWQG Moderate Additive CNS depression effects by the combination of Amoxapine and Olopatadine. Conjunctiva disorder [9A60] [49]
Mestranol DMG3F94 Minor Decreased metabolism of Amoxapine caused by Mestranol. Contraceptive management [QA21] [50]
Alfentanil DMVO0UB Moderate Additive CNS depression effects by the combination of Amoxapine and Alfentanil. Corneal disease [9A76-9A78] [37]
Remifentanil DMZTXCH Moderate Additive CNS depression effects by the combination of Amoxapine and Remifentanil. Corneal disease [9A76-9A78] [37]
Probucol DMVZQ2M Moderate Increased risk of prolong QT interval by the combination of Amoxapine and Probucol. Coronary atherosclerosis [BA80] [34]
Clofazimine DMEBOFW Moderate Increased risk of prolong QT interval by the combination of Amoxapine and Clofazimine. Crohn disease [DD70] [51]
Mifepristone DMGZQEF Major Increased risk of prolong QT interval by the combination of Amoxapine and Mifepristone. Cushing syndrome [5A70] [34]
Pasireotide DMHM7JS Major Increased risk of prolong QT interval by the combination of Amoxapine and Pasireotide. Cushing syndrome [5A70] [34]
Osilodrostat DMIJC9X Moderate Increased risk of prolong QT interval by the combination of Amoxapine and Osilodrostat. Cushing syndrome [5A70] [35]
Ethanol DMDRQZU Moderate Additive CNS depression effects by the combination of Amoxapine and Ethanol. Cystitis [GC00] [52]
Mepenzolate DM8YU2F Moderate Additive anticholinergic effects by the combination of Amoxapine and Mepenzolate. Digestive system disease [DE2Z] [32]
5-hydroxy-L-tryptophan DMDWZGJ Major Additive serotonergic effects by the combination of Amoxapine and 5-hydroxy-L-tryptophan. Discovery agent [N.A.] [53]
Oxybutynine DMJPBAX Moderate Additive anticholinergic effects by the combination of Amoxapine and Oxybutynine. Discovery agent [N.A.] [32]
Tetrabenazine DMYWQ0O Major Additive antidopaminergic effects by the combination of Amoxapine and Tetrabenazine. Dissociative neurological symptom disorder [6B60] [54]
Meclizine DMS7T13 Moderate Additive anticholinergic effects by the combination of Amoxapine and Meclizine. Dizziness and giddiness [MB48] [32]
Deutetrabenazine DMUPFLI Major Increased risk of prolong QT interval by the combination of Amoxapine and Deutetrabenazine. Dystonic disorder [8A02] [55]
Ingrezza DMVPLNC Moderate Additive CNS depression effects by the combination of Amoxapine and Ingrezza. Dystonic disorder [8A02] [56]
Fenfluramine DM0762O Moderate Additive serotonergic effects by the combination of Amoxapine and Fenfluramine. Epilepsy/seizure [8A61-8A6Z] [57]
Zonisamide DM0DTF7 Major Additive CNS depression effects by the combination of Amoxapine and Zonisamide. Epilepsy/seizure [8A61-8A6Z] [58]
Stiripentol DMMSDOY Moderate Decreased metabolism of Amoxapine caused by Stiripentol mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [59]
Fosphenytoin DMOX3LB Moderate Decreased metabolism of Amoxapine caused by Fosphenytoin mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [60]
Carbamazepine DMZOLBI Moderate Antagonize the effect of Amoxapine when combined with Carbamazepine. Epilepsy/seizure [8A61-8A6Z] [61]
Diphenhydramine DMKQTBA Moderate Additive anticholinergic effects by the combination of Amoxapine and Diphenhydramine. Episodic vestibular syndrome [AB31] [32]
Solifenacin DMG592Q Moderate Additive anticholinergic effects by the combination of Amoxapine and Solifenacin. Functional bladder disorder [GC50] [32]
Tolterodine DMSHPW8 Moderate Additive anticholinergic effects by the combination of Amoxapine and Tolterodine. Functional bladder disorder [GC50] [32]
Pentamidine DMHZJCG Moderate Increased risk of prolong QT interval by the combination of Amoxapine and Pentamidine. Fungal infection [1F29-1F2F] [34]
Terbinafine DMI6HUW Moderate Decreased metabolism of Amoxapine caused by Terbinafine mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [62]
Ketoconazole DMPZI3Q Moderate Increased risk of prolong QT interval by the combination of Amoxapine and Ketoconazole. Fungal infection [1F29-1F2F] [34]
Propantheline DM2EN6G Moderate Additive anticholinergic effects by the combination of Amoxapine and Propantheline. Gastric ulcer [DA60] [32]
Cisapride DMY7PED Major Increased risk of prolong QT interval by the combination of Amoxapine and Cisapride. Gastro-oesophageal reflux disease [DA22] [34]
Sunitinib DMCBJSR Moderate Increased risk of prolong QT interval by the combination of Amoxapine and Sunitinib. Gastrointestinal stromal tumour [2B5B] [34]
Acetazolamide DM1AF5U Minor as urine pH determines the ionization state of weakly acidic or weakly alkaline drugs. Amoxapine caused by Acetazolamide mediated altered urine pH. Glaucoma [9C61] [63]
Isoflurophate DMBSK7X Moderate Antagonize the effect of Amoxapine when combined with Isoflurophate. Glaucoma [9C61] [46]
Pilocarpine DMV9ADG Moderate Antagonize the effect of Amoxapine when combined with Pilocarpine. Glaucoma [9C61] [46]
Carvedilol DMHTEAO Moderate Increased plasma concentrations of Amoxapine and Carvedilol due to competitive inhibition of the same metabolic pathway. Heart failure [BD10-BD1Z] [60]
Procarbazine DMIK367 Major Additive serotonergic effects by the combination of Amoxapine and Procarbazine. Hodgkin lymphoma [2B30] [30]
Fostemsavir DM50ILT Moderate Increased risk of prolong QT interval by the combination of Amoxapine and Fostemsavir. Human immunodeficiency virus disease [1C60-1C62] [64]
Cobicistat DM6L4H2 Moderate Decreased metabolism of Amoxapine caused by Cobicistat mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [65]
Efavirenz DMC0GSJ Major Increased risk of prolong QT interval by the combination of Amoxapine and Efavirenz. Human immunodeficiency virus disease [1C60-1C62] [66]
Saquinavir DMG814N Major Increased risk of prolong QT interval by the combination of Amoxapine and Saquinavir. Human immunodeficiency virus disease [1C60-1C62] [67]
Rilpivirine DMJ0QOW Moderate Increased risk of prolong QT interval by the combination of Amoxapine and Rilpivirine. Human immunodeficiency virus disease [1C60-1C62] [34]
Atazanavir DMSYRBX Moderate Decreased metabolism of Amoxapine caused by Atazanavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [68]
Cinacalcet DMCX0K3 Moderate Decreased metabolism of Amoxapine caused by Cinacalcet mediated inhibition of CYP450 enzyme. Hyper-parathyroidism [5A51] [40]
Verapamil DMA7PEW Moderate Decreased metabolism of Amoxapine caused by Verapamil mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [69]
Labetalol DMK8U72 Moderate Increased plasma concentrations of Amoxapine and Labetalol due to competitive inhibition of the same metabolic pathway. Hypertension [BA00-BA04] [60]
Givosiran DM5PFIJ Moderate Decreased metabolism of Amoxapine caused by Givosiran mediated inhibition of CYP450 enzyme. Inborn porphyrin/heme metabolism error [5C58] [70]
Belladonna DM2RBWK Moderate Additive anticholinergic effects by the combination of Amoxapine and Belladonna. Infectious gastroenteritis/colitis [1A40] [32]
Amantadine DMS3YE9 Moderate Additive anticholinergic effects by the combination of Amoxapine and Amantadine. Influenza [1E30-1E32] [71]
Berotralstat DMWA2DZ Moderate Decreased metabolism of Amoxapine caused by Berotralstat mediated inhibition of CYP450 enzyme. Innate/adaptive immunodeficiency [4A00] [72]
Propiomazine DMKY8V1 Moderate Increased plasma concentrations of Amoxapine and Propiomazine due to competitive inhibition of the same metabolic pathway. Insomnia [7A00-7A0Z] [73]
ITI-007 DMUQ1DO Moderate Additive anticholinergic effects by the combination of Amoxapine and ITI-007. Insomnia [7A00-7A0Z] [32]
Polyethylene glycol DM4I1JP Moderate Increased risk of lowers seizure threshold by the combination of Amoxapine and Polyethylene glycol. Irritable bowel syndrome [DD91] [34]
Clidinium DMUMQZ0 Moderate Additive anticholinergic effects by the combination of Amoxapine and Clidinium. Irritable bowel syndrome [DD91] [32]
Dicyclomine DMZSDGX Moderate Additive anticholinergic effects by the combination of Amoxapine and Dicyclomine. Irritable bowel syndrome [DD91] [32]
Physostigmine DM2N0TO Moderate Antagonize the effect of Amoxapine when combined with Physostigmine. Lips/oral mucosa miscellaneous disorder [DA02] [39]
Glycerol phenylbutyrate DMDGRQO Moderate Decreased metabolism of Amoxapine caused by Glycerol phenylbutyrate mediated inhibition of CYP450 enzyme. Liver disease [DB90-DB9Z] [35]
Crizotinib DM4F29C Major Increased risk of prolong QT interval by the combination of Amoxapine and Crizotinib. Lung cancer [2C25] [74]
Ceritinib DMB920Z Major Increased risk of prolong QT interval by the combination of Amoxapine and Ceritinib. Lung cancer [2C25] [34]
Dacomitinib DMOH8VY Moderate Decreased metabolism of Amoxapine caused by Dacomitinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [75]
Osimertinib DMRJLAT Major Increased risk of prolong QT interval by the combination of Amoxapine and Osimertinib. Lung cancer [2C25] [76]
Selpercatinib DMZR15V Major Increased risk of prolong QT interval by the combination of Amoxapine and Selpercatinib. Lung cancer [2C25] [35]
Lumefantrine DM29GAD Major Increased risk of prolong QT interval by the combination of Amoxapine and Lumefantrine. Malaria [1F40-1F45] [40]
Halofantrine DMOMK1V Major Increased risk of prolong QT interval by the combination of Amoxapine and Halofantrine. Malaria [1F40-1F45] [77]
Chloroquine DMSI5CB Major Increased risk of prolong QT interval by the combination of Amoxapine and Chloroquine. Malaria [1F40-1F45] [78]
Hydroxychloroquine DMSIVND Major Increased risk of prolong QT interval by the combination of Amoxapine and Hydroxychloroquine. Malaria [1F40-1F45] [78]
Primaquine DMWQ16I Moderate Increased risk of prolong QT interval by the combination of Amoxapine and Primaquine. Malaria [1F40-1F45] [34]
Inotuzumab ozogamicin DMAC130 Moderate Increased risk of prolong QT interval by the combination of Amoxapine and Inotuzumab ozogamicin. Malignant haematopoietic neoplasm [2B33] [35]
Arsenic trioxide DM61TA4 Major Increased risk of prolong QT interval by the combination of Amoxapine and Arsenic trioxide. Mature B-cell lymphoma [2A85] [79]
Vemurafenib DM62UG5 Major Increased risk of prolong QT interval by the combination of Amoxapine and Vemurafenib. Melanoma [2C30] [34]
LGX818 DMNQXV8 Moderate Increased risk of prolong QT interval by the combination of Amoxapine and LGX818. Melanoma [2C30] [80]
Ethinyl estradiol DMODJ40 Minor Decreased metabolism of Amoxapine caused by Ethinyl estradiol. Menopausal disorder [GA30] [50]
Allopregnanolone DMNLHAC Moderate Additive CNS depression effects by the combination of Amoxapine and Allopregnanolone. Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z] [81]
Flibanserin DM70DTN Moderate Additive CNS depression effects by the combination of Amoxapine and Flibanserin. Mood disorder [6A60-6E23] [82]
Panobinostat DM58WKG Major Increased risk of prolong QT interval by the combination of Amoxapine and Panobinostat. Multiple myeloma [2A83] [83]
Thalidomide DM70BU5 Moderate Additive CNS depression effects by the combination of Amoxapine and Thalidomide. Multiple myeloma [2A83] [84]
Siponimod DM2R86O Major Increased risk of ventricular arrhythmias by the combination of Amoxapine and Siponimod. Multiple sclerosis [8A40] [40]
Fingolimod DM5JVAN Major Increased risk of ventricular arrhythmias by the combination of Amoxapine and Fingolimod. Multiple sclerosis [8A40] [34]
Ozanimod DMT6AM2 Moderate Additive serotonergic effects by the combination of Amoxapine and Ozanimod. Multiple sclerosis [8A40] [85]
Romidepsin DMT5GNL Moderate Increased risk of prolong QT interval by the combination of Amoxapine and Romidepsin. Mycosis fungoides [2B01] [34]
Fedratinib DM4ZBK6 Moderate Decreased metabolism of Amoxapine caused by Fedratinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [35]
Nilotinib DM7HXWT Major Increased risk of prolong QT interval by the combination of Amoxapine and Nilotinib. Myeloproliferative neoplasm [2A20] [34]
Imatinib DM7RJXL Moderate Decreased metabolism of Amoxapine caused by Imatinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [86]
Dasatinib DMJV2EK Moderate Increased risk of prolong QT interval by the combination of Amoxapine and Dasatinib. Myeloproliferative neoplasm [2A20] [87]
Modafinil DMYILBE Moderate Decreased metabolism of Amoxapine caused by Modafinil mediated inhibition of CYP450 enzyme. Narcolepsy [7A20] [40]
Phenindamine DMDTC7R Moderate Additive anticholinergic effects by the combination of Amoxapine and Phenindamine. Nasopharyngitis [CA00] [32]
Dimenhydrinate DM264B3 Moderate Additive anticholinergic effects by the combination of Amoxapine and Dimenhydrinate. Nausea/vomiting [MD90] [32]
Promethazine DM6I5GR Moderate Increased plasma concentrations of Amoxapine and Promethazine due to competitive inhibition of the same metabolic pathway. Nausea/vomiting [MD90] [73]
Cyclizine DM9G7BS Moderate Additive anticholinergic effects by the combination of Amoxapine and Cyclizine. Nausea/vomiting [MD90] [32]
Metoclopramide DMFA5MY Major Additive antidopaminergic effects by the combination of Amoxapine and Metoclopramide. Nausea/vomiting [MD90] [88]
Granisetron DMIUW25 Major Increased risk of prolong QT interval by the combination of Amoxapine and Granisetron. Nausea/vomiting [MD90] [34]
Dolasetron DMMG26Z Major Increased risk of prolong QT interval by the combination of Amoxapine and Dolasetron. Nausea/vomiting [MD90] [34]
Ondansetron DMOTQ1I Major Additive serotonergic effects by the combination of Amoxapine and Ondansetron. Nausea/vomiting [MD90] [34]
Bupropion DM5PCS7 Major Decreased metabolism of Amoxapine caused by Bupropion mediated inhibition of CYP450 enzyme. Nicotine use disorder [6C4A] [34]
Entrectinib DMMPTLH Moderate Increased risk of prolong QT interval by the combination of Amoxapine and Entrectinib. Non-small cell lung cancer [2C25] [40]
Sibutramine DMFJTDI Major Additive serotonergic effects by the combination of Amoxapine and Sibutramine. Obesity [5B80-5B81] [89]
Lorcaserin DMG6OYJ Major Additive serotonergic effects by the combination of Amoxapine and Lorcaserin. Obesity [5B80-5B81] [90]
Dexfenfluramine DMJ7YDS Major Additive serotonergic effects by the combination of Amoxapine and Dexfenfluramine. Obesity [5B80-5B81] [28]
Levomethadyl Acetate DM06HG5 Major Increased risk of prolong QT interval by the combination of Amoxapine and Levomethadyl Acetate. Opioid use disorder [6C43] [35]
Lofexidine DM1WXA6 Moderate Additive CNS depression effects by the combination of Amoxapine and Lofexidine. Opioid use disorder [6C43] [35]
Apraclonidine DMO4PVE Moderate Additive CNS depression effects by the combination of Amoxapine and Apraclonidine. Optic nerve disorder [9C40] [91]
Rucaparib DM9PVX8 Moderate Increased risk of prolong QT interval by the combination of Amoxapine and Rucaparib. Ovarian cancer [2C73] [34]
Pentazocine DM1XBHS Moderate Additive CNS depression effects by the combination of Amoxapine and Pentazocine. Pain [MG30-MG3Z] [37]
Dextropropoxyphene DM23HCX Major Additive CNS depression effects by the combination of Amoxapine and Dextropropoxyphene. Pain [MG30-MG3Z] [92]
Butorphanol DM5KYPJ Moderate Additive CNS depression effects by the combination of Amoxapine and Butorphanol. Pain [MG30-MG3Z] [37]
Oxymorphone DM65AGJ Moderate Additive CNS depression effects by the combination of Amoxapine and Oxymorphone. Pain [MG30-MG3Z] [37]
Levorphanol DMGS80V Moderate Additive CNS depression effects by the combination of Amoxapine and Levorphanol. Pain [MG30-MG3Z] [37]
Dezocine DMJDB0Y Moderate Additive CNS depression effects by the combination of Amoxapine and Dezocine. Pain [MG30-MG3Z] [37]
Flavoxate DMKV4NL Moderate Additive anticholinergic effects by the combination of Amoxapine and Flavoxate. Pain [MG30-MG3Z] [32]
Nalbuphine DMOSQGU Moderate Additive CNS depression effects by the combination of Amoxapine and Nalbuphine. Pain [MG30-MG3Z] [37]
Buprenorphine DMPRI8G Moderate Additive CNS depression effects by the combination of Amoxapine and Buprenorphine. Pain [MG30-MG3Z] [37]
Hydrocodone DMQ2JO5 Moderate Additive CNS depression effects by the combination of Amoxapine and Hydrocodone. Pain [MG30-MG3Z] [37]
Triclabendazole DMPWGBR Moderate Increased risk of prolong QT interval by the combination of Amoxapine and Triclabendazole. Parasitic worm infestation [1F90] [34]
Safinamide DM0YWJC Major Additive serotonergic effects by the combination of Amoxapine and Safinamide. Parkinsonism [8A00] [85]
Pergolide DM14MAE Moderate Antagonize the effect of Amoxapine when combined with Pergolide. Parkinsonism [8A00] [93]
Opicapone DM1BKA6 Moderate Additive hypotensive effects by the combination of Amoxapine and Opicapone. Parkinsonism [8A00] [93]
Rasagiline DM3WKQ4 Major Additive serotonergic effects by the combination of Amoxapine and Rasagiline. Parkinsonism [8A00] [30]
Biperiden DME78OA Moderate Additive anticholinergic effects by the combination of Amoxapine and Biperiden. Parkinsonism [8A00] [32]
Levodopa DMN3E57 Moderate Antagonize the effect of Amoxapine when combined with Levodopa. Parkinsonism [8A00] [93]
Pimavanserin DMR7IVC Moderate Increased risk of prolong QT interval by the combination of Amoxapine and Pimavanserin. Parkinsonism [8A00] [94]
Bromocriptine DMVE3TK Moderate Antagonize the effect of Amoxapine when combined with Bromocriptine. Parkinsonism [8A00] [93]
Orphenadrine DMW542E Moderate Additive anticholinergic effects by the combination of Amoxapine and Orphenadrine. Parkinsonism [8A00] [32]
Apomorphine DMX38HQ Moderate Increased risk of prolong QT interval by the combination of Amoxapine and Apomorphine. Parkinsonism [8A00] [34]
Methylscopolamine DM5VWOB Moderate Additive anticholinergic effects by the combination of Amoxapine and Methylscopolamine. Peptic ulcer [DA61] [32]
Famotidine DMRL3AB Moderate Increased risk of prolong QT interval by the combination of Amoxapine and Famotidine. Peptic ulcer [DA61] [40]
Macimorelin DMQYJIR Major Increased risk of prolong QT interval by the combination of Amoxapine and Macimorelin. Pituitary gland disorder [5A60-5A61] [95]
Lefamulin DME6G97 Major Increased risk of prolong QT interval by the combination of Amoxapine and Lefamulin. Pneumonia [CA40] [96]
Degarelix DM3O8QY Moderate Increased risk of prolong QT interval by the combination of Amoxapine and Degarelix. Prostate cancer [2C82] [35]
ABIRATERONE DM8V75C Moderate Increased risk of prolong QT interval by the combination of Amoxapine and ABIRATERONE. Prostate cancer [2C82] [35]
Nilutamide DMFN07X Moderate Increased risk of prolong QT interval by the combination of Amoxapine and Nilutamide. Prostate cancer [2C82] [35]
Enzalutamide DMGL19D Moderate Increased risk of prolong QT interval by the combination of Amoxapine and Enzalutamide. Prostate cancer [2C82] [35]
Relugolix DMK7IWL Moderate Increased risk of prolong QT interval by the combination of Amoxapine and Relugolix. Prostate cancer [2C82] [35]
Bicalutamide DMZMSPF Moderate Increased risk of prolong QT interval by the combination of Amoxapine and Bicalutamide. Prostate cancer [2C82] [35]
Levomepromazine DMIKFEL Moderate Increased plasma concentrations of Amoxapine and Levomepromazine due to competitive inhibition of the same metabolic pathway. Psychotic disorder [6A20-6A25] [73]
Gatifloxacin DMSL679 Major Increased risk of prolong QT interval by the combination of Amoxapine and Gatifloxacin. Respiratory infection [CA07-CA4Z] [97]
Neupro DMHEAB1 Moderate Antagonize the effect of Amoxapine when combined with Neupro. Restless legs syndrome [7A80] [93]
Quetiapine DM1N62C Moderate Increased risk of prolong QT interval by the combination of Amoxapine and Quetiapine. Schizophrenia [6A20] [34]
Mesoridazine DM2ZGAN Major Increased risk of prolong QT interval by the combination of Amoxapine and Mesoridazine. Schizophrenia [6A20] [34]
Thioridazine DM35M8J Major Increased risk of prolong QT interval by the combination of Amoxapine and Thioridazine. Schizophrenia [6A20] [98]
Aripiprazole DM3NUMH Moderate Additive anticholinergic effects by the combination of Amoxapine and Aripiprazole. Schizophrenia [6A20] [32]
Iloperidone DM6AUFY Major Increased risk of prolong QT interval by the combination of Amoxapine and Iloperidone. Schizophrenia [6A20] [34]
Paliperidone DM7NPJS Moderate Increased risk of prolong QT interval by the combination of Amoxapine and Paliperidone. Schizophrenia [6A20] [34]
Perphenazine DMA4MRX Moderate Increased plasma concentrations of Amoxapine and Perphenazine due to competitive inhibition of the same metabolic pathway. Schizophrenia [6A20] [73]
Molindone DMAH70G Moderate Additive anticholinergic effects by the combination of Amoxapine and Molindone. Schizophrenia [6A20] [32]
Thiothixene DMDINC4 Moderate Additive anticholinergic effects by the combination of Amoxapine and Thiothixene. Schizophrenia [6A20] [32]
Trifluoperazine DMKBYWI Moderate Increased plasma concentrations of Amoxapine and Trifluoperazine due to competitive inhibition of the same metabolic pathway. Schizophrenia [6A20] [73]
Risperidone DMN6DXL Moderate Additive anticholinergic effects by the combination of Amoxapine and Risperidone. Schizophrenia [6A20] [32]
Amisulpride DMSJVAM Major Increased risk of prolong QT interval by the combination of Amoxapine and Amisulpride. Schizophrenia [6A20] [99]
Asenapine DMSQZE2 Moderate Increased risk of prolong QT interval by the combination of Amoxapine and Asenapine. Schizophrenia [6A20] [34]
Pimozide DMW83TP Major Increased risk of prolong QT interval by the combination of Amoxapine and Pimozide. Schizophrenia [6A20] [35]
Fentanyl DM8WAHT Major Additive serotonergic effects by the combination of Amoxapine and Fentanyl. Sensation disturbance [MB40] [28]
Sufentanil DMU7YEL Moderate Additive CNS depression effects by the combination of Amoxapine and Sufentanil. Sensation disturbance [MB40] [37]
Vardenafil DMTBGW8 Moderate Increased risk of prolong QT interval by the combination of Amoxapine and Vardenafil. Sexual dysfunction [HA00-HA01] [34]
Armodafinil DMGB035 Moderate Decreased metabolism of Amoxapine caused by Armodafinil mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [40]
LEE011 DMMX75K Major Increased risk of prolong QT interval by the combination of Amoxapine and LEE011. Solid tumour/cancer [2A00-2F9Z] [34]
Vandetanib DMRICNP Major Increased risk of prolong QT interval by the combination of Amoxapine and Vandetanib. Solid tumour/cancer [2A00-2F9Z] [34]
Triptorelin DMTK4LS Moderate Increased risk of prolong QT interval by the combination of Amoxapine and Triptorelin. Solid tumour/cancer [2A00-2F9Z] [35]
Doxorubicin DMVP5YE Moderate Increased risk of prolong QT interval by the combination of Amoxapine and Doxorubicin. Solid tumour/cancer [2A00-2F9Z] [34]
Telavancin DM58VQX Moderate Increased risk of prolong QT interval by the combination of Amoxapine and Telavancin. Staphylococcal/streptococcal disease [1B5Y] [34]
Adenosine DMM2NSK Moderate Increased risk of ventricular arrhythmias by the combination of Amoxapine and Adenosine. Supraventricular tachyarrhythmia [BC81] [34]
Lenvatinib DMB1IU4 Moderate Increased risk of prolong QT interval by the combination of Amoxapine and Lenvatinib. Thyroid cancer [2D10] [34]
Cabozantinib DMIYDT4 Major Increased risk of prolong QT interval by the combination of Amoxapine and Cabozantinib. Thyroid cancer [2D10] [35]
Papaverine DMCA9QP Major Increased risk of prolong QT interval by the combination of Amoxapine and Papaverine. Tonus and reflex abnormality [MB47] [100]
Tizanidine DMR2IQ4 Moderate Additive CNS depression effects by the combination of Amoxapine and Tizanidine. Tonus and reflex abnormality [MB47] [101]
Tacrolimus DMZ7XNQ Moderate Increased risk of prolong QT interval by the combination of Amoxapine and Tacrolimus. Transplant rejection [NE84] [34]
Atropine DMEN6X7 Moderate Additive anticholinergic effects by the combination of Amoxapine and Atropine. Unspecific substance harmful effect [NE6Z] [32]
Astemizole DM2HN6Q Moderate Increased risk of prolong QT interval by the combination of Amoxapine and Astemizole. Vasomotor/allergic rhinitis [CA08] [34]
Chlorpheniramine DM5URA2 Moderate Additive anticholinergic effects by the combination of Amoxapine and Chlorpheniramine. Vasomotor/allergic rhinitis [CA08] [32]
Methdilazine DMAUHQX Moderate Increased plasma concentrations of Amoxapine and Methdilazine due to competitive inhibition of the same metabolic pathway. Vasomotor/allergic rhinitis [CA08] [73]
Carbinoxamine DMCT31R Moderate Additive anticholinergic effects by the combination of Amoxapine and Carbinoxamine. Vasomotor/allergic rhinitis [CA08] [32]
Trimeprazine DMEMV9D Moderate Increased plasma concentrations of Amoxapine and Trimeprazine due to competitive inhibition of the same metabolic pathway. Vasomotor/allergic rhinitis [CA08] [102]
Brompheniramine DMFOVSD Moderate Additive anticholinergic effects by the combination of Amoxapine and Brompheniramine. Vasomotor/allergic rhinitis [CA08] [32]
Acrivastine DMTIGA0 Moderate Additive anticholinergic effects by the combination of Amoxapine and Acrivastine. Vasomotor/allergic rhinitis [CA08] [32]
Azatadine DMZ80SB Moderate Additive anticholinergic effects by the combination of Amoxapine and Azatadine. Vasomotor/allergic rhinitis [CA08] [32]
Procainamide DMNMXR8 Major Increased risk of prolong QT interval by the combination of Amoxapine and Procainamide. Ventricular tachyarrhythmia [BC71] [34]
Propafenone DMPIBJK Moderate Increased risk of prolong QT interval by the combination of Amoxapine and Propafenone. Ventricular tachyarrhythmia [BC71] [103]
Flecainide DMSQDLE Moderate Increased risk of prolong QT interval by the combination of Amoxapine and Flecainide. Ventricular tachyarrhythmia [BC71] [103]
Amiodarone DMUTEX3 Major Increased risk of prolong QT interval by the combination of Amoxapine and Amiodarone. Ventricular tachyarrhythmia [BC71] [34]
⏷ Show the Full List of 225 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
FD&C blue no. 2 E00446 2723854 Colorant
Stearic acid E00079 5281 Emulsifying agent; Solubilizing agent; Viscosity-controlling agent; lubricant
Sunset yellow FCF E00255 17730 Colorant
Brushite E00392 104805 Diluent
Calcium hydrogenphosphate E00294 24441 Diluent
Magnesium stearate E00208 11177 lubricant
⏷ Show the Full List of 6 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Amoxapine 100 mg tablet 100 mg Oral Tablet Oral
Amoxapine 150 mg tablet 150 mg Oral Tablet Oral
Amoxapine 50 mg tablet 50 mg Oral Tablet Oral
Amoxapine 25 mg tablet 25 mg Oral Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 201).
2 FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 072688.
3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
4 BDDCS applied to over 900 drugs
5 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
6 FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
7 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
8 Effects of acute and chronic treatment with amoxapine and cericlamine on the sleep-wakefulness cycle in the rat. Neuropharmacology. 1994 Aug;33(8):1017-25.
9 Addition of amoxapine improves positive and negative symptoms in a patient with schizophrenia. Ther Adv Psychopharmacol. 2013 Dec;3(6):340-2.
10 Inhibitory effects of anticancer drugs on dextromethorphan-O-demethylase activity in human liver microsomes. Cancer Chemother Pharmacol. 1993;32(6):491-5.
11 Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6. Brain Res Mol Brain Res. 2004 Oct 22;129(1-2):117-23.
12 CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance. Curr Oncol Rep. 2010 Jan;12(1):7-15.
13 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
14 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
15 Inhibition of cytochrome P450 2D6: structure-activity studies using a series of quinidine and quinine analogues. Chem Res Toxicol. 2003 Apr;16(4):450-9.
16 Effects of propofol on human hepatic microsomal cytochrome P450 activities. Xenobiotica. 1998 Sep;28(9):845-53.
17 Pharmacogenetics of schizophrenia. Am J Med Genet. 2000 Spring;97(1):98-106.
18 Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol. 1999 Mar;73(2):65-70.
19 Structure-activity relationship for human cytochrome P450 substrates and inhibitors. Drug Metab Rev. 2002 Feb-May;34(1-2):69-82.
20 Augmentation effect of combination therapy of aripiprazole and antidepressants on forced swimming test in mice. Psychopharmacology (Berl). 2009 Sep;206(1):97-107.
21 Treatment of comorbid pain with serotonin norepinephrine reuptake inhibitors. CNS Spectr. 2008 Jul;13(7 Suppl 11):22-6.
22 Invivo antioxidant status: a putative target of antidepressant action. Prog Neuropsychopharmacol Biol Psychiatry. 2009 Mar 17;33(2):220-8.
23 Differential involvement of the norepinephrine, serotonin and dopamine reuptake transporter proteins in cocaine-induced taste aversion. Pharmacol Biochem Behav. 2009 Jul;93(1):75-81.
24 Clinically relevant drug interactions with new generation antidepressants and antipsychotics. Ther Umsch. 2009 Jun;66(6):485-92.
25 2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6.
26 Antidepressants suppress production of the Th1 cytokine interferon-gamma, independent of monoamine transporter blockade. Eur Neuropsychopharmacol. 2006 Oct;16(7):481-90.
27 Multi-target therapeutics: when the whole is greater than the sum of the parts. Drug Discov Today. 2007 Jan;12(1-2):34-42.
28 Achamallah NS "Visual hallucinations after combining fluoxetine and dextromethorphan ." Am J Psychiatry 149 (1992): 1406. [PMID: 1530079]
29 Albers LJ, Reist C, Helmeste D, Vu R, Tang SW "Paroxetine shifts imipramine metabolism." Psychiatry Res 59 (1996): 189-96. [PMID: 8930024]
30 Boyer EW, Shannon M "The serotonin syndrome." N Engl J Med 352 (2005): 1112-20. [PMID: 15784664]
31 Bhatara VS, Magnus RD, Paul KL, Preskorn SH "Serotonin syndrome induced by venlafaxine and fluoxetine: a case study in polypharmacy and potential pharmacodynamic and pharmacokinetic mechanisms." Ann Pharmacother 32 (1998): 432-6. [PMID: 9562139]
32 Cohen MA, Alfonso CA, Mosquera M. Development of urinary retention during treatment with clozapine and meclizine [published correction appears in Am J Psychiatry 1994 Jun;151(6):952]. Am J Psychiatry. 1994;151(4):619-620. [PMID: 8147469]
33 Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
34 Canadian Pharmacists Association.
35 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
36 Product Information. Xospata (gilteritinib). Astellas Pharma US, Inc, Deerfield, IL.
37 Vizcaychipi MP, Walker S, Palazzo M "Serotonin syndrome triggered by tramadol." Br J Anaesth 99 (2007): 919. [PMID: 18006535]
38 Kulik AV, Wilbur R "Delirium and stereotypy from anticholinergic antiparkinson drugs." Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82. [PMID: 7202232]
39 Beers MH, Ouslander JG, Rollingher I, Reuben DB, Brooks J, Beck JC "Explicit criteria for determining inappropriate medication use in nursing home residents." Arch Intern Med 151 (1991): 1825-32. [PMID: 1888249]
40 Cerner Multum, Inc. "Australian Product Information.".
41 Hollingshead LM, Faulds D, Fitton A "Bepridil. A review of its pharmacological properties and therapeutic use in stable angina pectoris." Drugs 44 (1992): 835-57. [PMID: 1280569]
42 Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
43 Ball P "Quinolone-induced QT interval prolongation: a not-so-unexpected class effect." J Antimicrob Chemother 45 (2000): 557-9. [PMID: 10797074]
44 Bergeron L, Boule M, Perreault S "Serotonin toxicity associated with concomitant use of linezolid." Ann Pharmacother 39 (2005): 956-61. [PMID: 15827071]
45 Eronen M, Putkonen H, Hallikainen T, Vartiainen H "Lethal gastroenteritis associated with clozapine and loperamide." Am J Psychiatry 160 (2003): 2242-2243. [PMID: 14638602]
46 Multum Information Services, Inc. Expert Review Panel.
47 Product Information. Daurismo (glasdegib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
48 Cole JM, Sheehan AH, Jordan JK "Concomitant use of ipratropium and tiotropium in chronic obstructive plmonary disease." Ann Pharmacother 46 (2012): 1717-21. [PMID: 23170031]
49 Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7. [PMID: 3725002]
50 Edelbroek PM, Zitman FG, Knoppert-van der Klein EA, van Putten PM, de Wolff FA "Therapeutic drug monitoring of amitriptyline: impact of age, smoking and contraceptives on drug and metabolite levels in bulimic women." Clin Chim Acta 165 (1987): 177-87. [PMID: 3652444]
51 Product Information. Lamprene (clofazimine). Novartis Pharmaceuticals, East Hanover, NJ.
52 Ciraulo DA, Alderson LM, Chapron DJ, Jaffe JH, Subbarao B, Kramer PA "Imipramine disposition in alcoholics." J Clin Psychopharmacol 2 (1982): 2-7. [PMID: 7068940]
53 Ciraulo DA, Shader RI "Fluoxetine drug-drug interactions: I. Antidepressants and antipsychotics." J Clin Psychopharmacol 10 (1990): 48-50. [PMID: 1968472]
54 Burke RE, Fahn S, Mayeux R, Weinberg H, Louis K, Willner JH "Neuroleptic malignant syndrome caused by dopamine-depleting drugs in a patient with Huntington disease." Neurology 31 (1981): 1022-5. [PMID: 6115336]
55 Product Information. Austedo (deutetrabenazine). Teva Pharmaceuticals USA, North Wales, PA.
56 Product Information. Ingrezza (valbenazine). Neurocrine Biosciences, Inc., San Diego, CA.
57 Fogelson DL "Fenfluramine and the cytochrome P450 system." Am J Psychiatry 154 (1997): 436-7. [PMID: 9054800]
58 Product Information. Zonegran (zonisamide) Elan Pharmaceuticals, S. San Francisco, CA.
59 EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports.".
60 Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
61 Brosen K, Kragh-Sorensen P "Concomitant intake of nortriptyline and carbamazepine." Ther Drug Monit 15 (1993): 258-60. [PMID: 8333008]
62 AbdelRahman SM, Gotschall RR, Kauffman RE, Leeder JS, Kearns GL "Investigation of terbinafine as a CYP2D6 inhibitor in vivo." Clin Pharmacol Ther 65 (1999): 465-72. [PMID: 10340911]
63 Gram LF, Kofod B, Christiansen J, Rafaelsen OJ "Imipramine metabolism: pH-dependent distribution and urinary excretion." Clin Pharmacol Ther 12 (1971): 239-44. [PMID: 5554940]
64 Product Information. Rukobia (fostemsavir). ViiV Healthcare, Research Triangle Park, NC.
65 Product Information. Stribild (cobicistat/elvitegravir/emtricitabine/tenofov). Gilead Sciences, Foster City, CA.
66 Product Information. Sustiva (efavirenz). DuPont Pharmaceuticals, Wilmington, DE.
67 Anson BD, Weaver JG, Ackerman MJ, et al. "Blockade of HERG channels by HIV protease inhibitors." Lancet 365 (2005): 682-686. [PMID: 15721475]
68 Eap CB, Bender S, Gastpar M, et al "Steady state plasma levels of the enantiomers of trimipramine and its metabolites in CYP2D6-, CYP2C19- and CYP3A4/5-phenotyped patients." Ther Drug Monit 22 (2000): 209-14. [PMID: 10774635]
69 Hermann DJ, Krol TF, Dukes GE, et al "Comparison of verapamil, diltiazem, and labetalol on the bioavailability and metabolism of imipramine." J Clin Pharmacol 32 (1992): 176-83. [PMID: 1613128]
70 Product Information. Givlaari (givosiran). Alnylam Pharmaceuticals, Cambridge, MA.
71 Postma JU, van Tilburg W "Visual hallucinations and delirium during treatment with amantadine (Symmetrel)." J Am Geriatr Soc 23 (1975): 212-5. [PMID: 123540]
72 Product Information. Orladeyo (berotralstat). BioCryst Pharmaceuticals Inc, Durham, NC.
73 Bock JL, Nelson JC, Gray S, Jatlow PI "Desipramine hydroxylation: variability and effect of antipsychotic drugs." Clin Pharmacol Ther 33 (1983): 322-8. [PMID: 6130865]
74 Product Information. Xalkori (crizotinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
75 Product Information. Vizimpro (dacomitinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
76 Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
77 Abernethy DR, Wesche DL, Barbey JT, et al. "Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation." Br J Clin Pharmacol 51 (2001): 231-7. [PMID: 11298069]
78 Harper KM, Knapp DJ, Criswell HE, Breese GR "Vasopressin and alcohol: A multifaceted relationship." Psychopharmacology (Berl) 235 (2018): 3363-79. [PMID: 32936259]
79 Ohnishi K, Yoshida H, Shigeno K, et al. "Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia." Ann Intern Med 133 (2000): 881-5. [PMID: 11103058]
80 Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
81 Product Information. Zulresso (brexanolone). Sage Therapeutics, Inc., Cambridge, MA.
82 Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
83 Product Information. Farydak (panobinostat). Novartis Pharmaceuticals, East Hanover, NJ.
84 Product Information. Thalomid (thalidomide). Celgene Corporation, Warren, NJ.
85 Alvine G, Black DW, Tsuang D "Case of delirium secondary to phenelzine/L-tryptophan combination." J Clin Psychiatry 51 (1990): 311. [PMID: 2365671]
86 Product Information. Gleevec (imatinib mesylate). Novartis Pharmaceuticals, East Hanover, NJ.
87 Product Information. Sprycel (dasatinib). Bristol-Myers Squibb, Princeton, NJ.
88 Bateman DN, Rawlins MD, Simpson JM "Extrapyramidal reactions with metoclopramide." Br Med J (Clin Res Ed) 291 (1985): 930-2. [PMID: 3929968]
89 Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG "Serotonin syndrome resulting from drug interactions." Med J Aust 169 (1998): 523-5. [PMID: 9861909]
90 Product Information. Belviq (lorcaserin). Eisai Inc, Teaneck, NJ.
91 Product Information. Iopidine (apraclonidine). Alcon Laboratories Inc, Fort Worth, TX.
92 Abernethy DR, Greenblatt DJ, Steel K, Shader RI "Impairment of hepatic drug oxidation by propoxyphene." Ann Intern Med 97 (1982): 223-4. [PMID: 7103282]
93 Mims RB, Scott CL, Modebe O, Bethune JE "Inhibition of L-dopa-induced growth hormone stimulation by pyridoxine and chlorpromazine." J Clin Endocrinol Metab 40 (1975): 256-9. [PMID: 1117978]
94 Product Information. Nuplazid (pimavanserin). Accelis Pharma, East Windsor, NJ.
95 Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
96 Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
97 Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004): 55-6. [PMID: 14722399]
98 Bluhm RE, Wilkinson GR, Shelton R, Branch RA "Genetically determined drug-metabolizing activity and desipramine- associated cardiotoxicity: a case report." Clin Pharmacol Ther 53 (1993): 89-95. [PMID: 8422746]
99 Product Information. Barhemsys (amisulpride). Acacia Pharma, Inc, Indianapolis, IN.
100 Goto M, Sato M, Kitzazawa H, et.al "Papaverine-induced QT interval prolongation and ventricular fibrillation in a patient with a history of drug-induced QT prolongation." Intern Med 53 (2014): 1629-31. [PMID: 25088875]
101 Product Information. Zanaflex (tizanidine). Acorda Therapeutics, Hawthorne, NY.
102 Lee BS "Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs." J Clin Psychiatry 47 (1986): 571. [PMID: 3771507]
103 Katz MR "Raised serum levels of desipramine with the antiarrhythmic propafenone ." J Clin Psychiatry 52 (1991): 432-3. [PMID: 1938981]